Incisive Technologies is a medical device company focussed on empowering oral healthcare professionals and increasing the opportunity for preventive treatments globally.

Founded in 2012, Incisive’s lead technology builds on research from The University of Melbourne into a 100‑year mystery surrounding the cause of Molar Hypomineralisation (MH or MIH), commonly known as chalky teeth, found in ~1 in 5 children (Hubbard, 2021). The team’s research focused on understanding enamel, defects, and decay with the aim of improving clinical outcomes for patients. Through this research, they identified that protein has a high affinity for porous enamel (Mangum, 2010), which is present in certain defects and when enamel demineralises and early caries lesions form.

An enamel caries lesion is an early-stage of tooth decay where the outer surface of the tooth (enamel) starts to lose minerals. and affects 1 in 2 children and nearly all (90%) adults across their lifetime It hasn’t formed a cavity yet—the surface is usually still intact—but the enamel underneath becomes weakened, chalky, and porous.

This discovery prompted the team to explore how proteins could be harnessed as biomarkers to identify porous regions in tooth enamel (hydroxyapatite) and provide an objective, early warning sign of caries disease. This research led to the development of Incisive’s lead technology and the granting of patents across 22 jurisdictions in the Americas, Europe, and the Asia‑Pacific.

Company growth has accelerated in recent years, supported by a successful partnership with CareQuest Innovation Partners (Boston), the leading dental advocacy group in the US, along with two Australian grants (AusIndustry Accelerating Commercialisation and the Industry Growth Program). These initiatives have propelled Incisive’s translation efforts and manufacturing scale‑up in preparation for commercialisation and entry into the US market following FDA 510(k) clearance in 2023.

BlueCheck is the first product to be commercialised by Incisive Technologies, who are committed to advancing improvements in caries management. The company continues to collaborate with leading clinicians and academics to support the shift toward medical management of caries—similar to other chronic conditions—through earlier detection, prevention, and minimally invasive care. Incisive is engaged in multiple research and collaboration projects to deepen understanding of BlueCheck’s science, its role in clinical management, practice value, and how it can simplify early caries detection to reduce the burden of disease.

The US market is Incisive’s first launch market and represents a significant opportunity, with more than 225 million routine dental check‑ups conducted annually. The company is expanding its US team to support the introduction of BlueCheck and to help drive the evolution of oral care. Incisive is always seeking talented individuals who share a passion for advancing oral healthcare and addressing the global challenge of tooth decay.